Annual Report Reveals Steep Financial Decline, Nasdaq Delisting Threat, and Conflicting Business Identity
PASW sits 38% above its 52-week low of $0.161 on light trading volume (0.1× avg).
Summary
Ping An Biomedical Co., Ltd.'s annual report for fiscal year 2025 reveals a dramatic 61% revenue decline and an 899% surge in net loss, alongside a Nasdaq delisting notice for minimum bid price non-compliance and a confusing corporate identity shift from apparel SCM to biomedical without corresponding business changes.
Key Events · Corporate Governance and Compliance · PASW
-
Significant Revenue Decline
Revenue decreased by 61.0% to RMB 34.1 million (US$4.8 million) for fiscal year 2025, compared to RMB 87.6 million in 2024.
-
Massive Net Loss Increase
Net loss surged by 899.0% to RMB 12.8 million (US$1.8 million) in fiscal year 2025, up from RMB 1.28 million in 2024.
-
Nasdaq Delisting Threat
The company received a notice on November 24, 2025, for failing to meet Nasdaq's minimum $1 bid price continued listing requirement.
-
Conflicting Business Identity
Despite changing its name to 'Ping An Biomedical Co., Ltd.' in September 2025, the company's business overview in the filing remains focused on apparel supply chain management, creating a significant discrepancy.
Analysis · PASW · Manufacturing
The 20-F filing for Ping An Biomedical Co., Ltd. presents a highly concerning outlook, marked by severe financial deterioration with a dramatic 61.0% drop in revenue and a nearly tenfold increase in net losses for fiscal year 2025. The company faces a critical threat of delisting from Nasdaq due to non-compliance with the minimum bid price rule, which could significantly impact its public market access. A major red flag is the discrepancy between the company's recent name change to 'Ping An Biomedical Co., Ltd.' and its continued description of operations solely in apparel supply chain management, indicating either a lack of clear strategic direction or potentially misleading corporate identity. The substantial decline in market capitalization since its $15 million IPO just months prior further highlights a significant loss of investor confidence. Additionally, the report acknowledges ongoing material weaknesses in internal controls, which, despite some stated remediation efforts, underscore persistent governance challenges. Notably, this annual report does not mention the strategic investment announced in a 6-K filing on January 12, 2026, which is a significant omission given the 20-F's later filing date. Investors should exercise extreme caution due to these compounding negative factors and the apparent strategic and operational confusion.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASW was trading at $0.22 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.16 to $1.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.